PEAR - Pear Therapeutics expands program with Brightview on prescription digital therapeutics
- Pear Therapeutics and BrightView Health have expanded a pilot program providing prescription digital therapeutics for substance use disorders.
- The expansion means that Pear's ( NASDAQ: PEAR ) reSET and reSET-O therapeutics are now available to BrightView patients in Kentucky, Ohio, Delaware, Massachusetts, and Virginia.
- ReSET is a monotherapy for patients 18 years of age or older with substance use disorder, while reSET-O is used in combination with buprenorphine for opioid use disorder.
- Earlier in January, Pear ( PEAR ) expanded a partnership with Spero Health to provide the same two PDTs .
For further details see:
Pear Therapeutics expands program with Brightview on prescription digital therapeutics